Reference number(s)
2968-H

SPECIALTY QUANTITY LIMIT PROGRAM

BALVERSA (erdafitinib)

I. PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for treatment of urothelial carcinoma fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

II. COVERED QUANTITIES

Medication	Standard Limit	FDA-recommended dosing
Balversa 3 mg	84 per 28 days	The recommended starting dose is 8 mg (two 4 mg tablets) once daily, with a dose increase to 9 mg (three 3 mg tablets) once daily based on serum phosphate levels and tolerability at 14 to 21 days. The following dose adjustments may be necessary: - 8 mg (two 4 mg tablets) daily - 6 mg (two 3 mg tablets) daily - 5 mg (one 5 mg tablet) daily - 4 mg (one 4 mg tablet) daily
Balversa 4 mg	56 per 28 days	
Balversa 5 mg	28 per 28 days	

III. REFERENCES

1. Balversa [package insert]. Horsham, PA: Janssen Products, LP; April 2019.